L.V. VASILYEVA, M.I. TALYKOVA, E.V. GOSTEVA, V.I. ZOLOEDOV, L.V. ULYANOVA, E.YU. SUSLOVA

 Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia

Contact details:

Suslova E.Yu. — PhD (medicine), Associate Professor, Department of Propaedeutics of Internal Diseases

Address: 10 Studencheskaya St., Voronezh, Russian Federation, 394036, tel.: +7-951-567-02-12, e-mail: suslova_ekaterina2502@mail.ru

The study presents the results of examination of 92 patients with chronic obstructive pulmonary disease (COPD) aimed at identifying anemic syndrome. Anemia as a systemic manifestation of the disease was diagnosed in 29% of patients. It was found that in women this syndrome develops significantly more often and at an earlier stage than in men. By the erythrocytes morphology and the degree of iron saturation, anemia was normocytic and hypochromic in most patients. Reliable clinical features of the COPD course in patients with anemic syndrome were identified: anemia significantly worsens the condition of patients, mostly females, who often complain of shortness of breath; with the same degree of bronchial obstruction as male patients, women often suffer from impaired health and more frequently need hospital treatment.

Key words: chronic obstructive pulmonary disease, anemia, clinical features, gender differences.

REFERENCES

1. Barabanova E.N. GOLD (2017): what and why has changed in the global strategy for the treatment of chronic obstructive pulmonary disease. Pul’monologiya, 2017, no. 27 (2), pp. 274–282 (in Russ.).
2. Dvoretskiy L.I. Anemia in COPD patients: comorbidity or systemic manifestation? Pul’monologiya, 2012, no. 2, pp. 5–11 (in Russ.).
3. Evseychik E.S., Potapova I.I. Khronicheskaya obstruktivnaya bolezn’: sovremennye podkhody k diagnostike i lecheniyu s uchetom komorbidnosti: prakticheskoe posobie dlya vrachey [Chronic obstructive disease: modern approaches to diagnosis and treatment taking into account comorbidity: a practical guide for physicians]. Gomel, 2019. 24 p.
4. Nikitin V.A., Starodubtseva I.A., Vasil’eva L.V. et al. Comprehensive analysis of risk factors affecting the progression of chronic obstructive pulmonary disease. Terapevticheskiy arkhiv, 2018, vol. 90, no. 1, pp. 27–30 (in Russ.).
5. Respiratornaya meditsina: rukovodstvo. V 3 t., pod red. A.G. Chuchalina. 2-e izd., pererab. i dop. [Respiratory medicine: a guide. In 3 volumes, ed. A.G. Chuchalin. 2nd ed., revised. and additional]. Moscow: Litterra, 2017. Vol. 1. 640 p.
6. Calzetta L., Ritondo B.L., de Marco P. et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir. Med, 2021, vol. 15 (1), pp. 143–152.
7. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2020, available at: https://goldcopd.org/
8. Jacobs S.S., Krishnan J.A., Lederer D.J. et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, vol. 202 (10), rr. 121–141.
9. Sandelowsky H., Natalishvili N., Krakau I., Modin S.B., Nager A. COPD management by Swedish general practitioners — baseline results of the PRIMAIR study. Scand. J. Prim. Health Care, 2018, vol. 36 (1), rr. 5–13.
10. Lipson D.A., Crim C., Criner G.J. et al., Reduction in All-Cause Mortality with Fluticasone Furoate / Umeclidinium / Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med, 2020, vol. 201 (12), rr. 1508–1516.
11. Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med, 2017, vol. 196 (4), rr. 438–446.
12. Matsunaga K., Oishi K., Miravitlles et al. Time to Revise COPD Treatment Algorithm. Int. J. Chron. Obstruct. Pulmon. Dis, 2019, vol. 14, rr. 2229–2234.